HCATHealthcare · Health Information ServicesThe 6 Wall Street analysts covering Health Catalyst, Inc. hold a median 12-month price target of $2 — +8.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 13 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Health Catalyst, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (22): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HCAT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +8.1% from it.
Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $1.75 → $1.50 |
| 11 Aug 2026 | Citigroup | Maintains | Neutral | $2.50 → $2.00 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $2.00 → $3.00 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 26 June 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 26 June 2026 | Wells Fargo | Maintains | Equal-Weight | $1.00 → $1.75 |
| 12 May 2026 | Stephens & Co. | Maintains | Equal-Weight | — |
| 18 Mar 2026 | Wells Fargo | Downgrade | Equal-Weight | — |
| 13 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 13 Mar 2026 | Cantor Fitzgerald | Maintains | Neutral | — |
| 13 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 13 Mar 2026 | Stephens & Co. | Maintains | Equal-Weight | — |
| 13 Mar 2026 | Stifel | Maintains | Hold | — |
| 9 Jan 2026 | Citigroup | Maintains | Neutral | — |
| 11 Nov 2025 | Citigroup | Maintains | Neutral | — |
| 11 Nov 2025 | Stifel | Maintains | Hold | — |
| 11 Nov 2025 | Wells Fargo | Maintains | Overweight | — |
| 8 Oct 2025 | Evercore ISI Group | Maintains | In-Line | — |
| 8 Oct 2025 | Keybanc | Maintains | Overweight | — |
| 7 Oct 2025 | Cantor Fitzgerald | Reiterates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HCAT appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 84% of US stocks
Cheaper than 75% of US stocks
Cheaper than 20% of US stocks
Higher than 14% of US stocks
Higher than 62% of US stocks
Higher than 28% of US stocks
Higher than 6% of US stocks
Higher than 11% of US stocks
Higher than 34% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Health Catalyst, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Health Catalyst reported second-quarter 2026 revenue above the high end of its guidance range and adjusted EBITDA at the high end of its outlook. The company also outlined a strategic shift following the July 31 divestiture of its Vitalware and Med-Metrix businesses.
Why it matters — The earnings results and post-divestiture strategic shift indicate how HCAT is positioned after reshaping its business portfolio.
Health Catalyst, Inc. published the transcript of its Q2 2026 earnings call, as reported by Seeking Alpha. The excerpt contains only the transcript headline with no financial figures or management commentary.
Why it matters — HCAT watchers would review the earnings call transcript for management's discussion of the company's quarterly performance and outlook.
Zacks Investment Research reports that Health Catalyst's revenue and EPS for the quarter ended June 2026 provide a view of business performance relative to Wall Street estimates and year-ago figures. The report examines how key metrics compare with those benchmarks.
Why it matters — HCAT watchers would care because the comparison of key metrics to Wall Street estimates and prior-year results offers insight into the company's quarterly operating performance.
Health Catalyst reported Q2 earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share, and also surpassed revenue estimates. The result matches the $0.04 per share the company posted a year ago.
Why it matters — HCAT watchers would note that the company exceeded analyst expectations for both earnings and revenue in the quarter.
Health Catalyst reported its financial results for the quarter ended June 30, 2026. CEO Ben Albert said the company delivered a productive second quarter, exceeding the high end of its revenue guidance and meeting the midpoint of its adjusted EBITDA guidance.
Why it matters — Health Catalyst watchers would track this announcement because quarterly results indicate whether the company is meeting its financial guidance for its healthcare intelligence business.
The 6 Wall Street analysts covering Health Catalyst, Inc. have a median 12-month price target of $2, with estimates ranging from $1.75 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Health Catalyst, Inc., 2 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Health Catalyst, Inc. 52 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Aug 2026, Health Catalyst, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +8.1% from the last close, and Ticker Nerd's factor model ranks Health Catalyst, Inc. 52 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Health Catalyst, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HCAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.75 to $3 over the next 12 months.
Health Catalyst, Inc. returned -36.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Health Catalyst Inc. is a leading provider of data and analytics technology and services to healthcare organizations throughout the United States.
The most recent item we track (MarketBeat, 7 Aug 2026): "Health Catalyst Q2 Earnings Call Highlights". Health Catalyst reported second-quarter 2026 revenue above the high end of its guidance range and adjusted EBITDA at the high end of its outlook. The company also outlined a strategic shift following the July 31 divestiture of its Vitalware and Med-Metrix businesses.
Health Catalyst Inc. is a leading provider of data and analytics technology and services to healthcare organizations throughout the United States. The company operates in two primary segments: Technology, which encompasses cloud-based subscriptions, time-based licenses, maintenance, and support for its data platforms and analytics applications; and Professional Services, including analytics, implementation, strategic advisory, outsourcing, and improvement services to help clients configure and utilize its offerings. At the core of its solutions is the Health Catalyst Ignite platform, a cloud-based ecosystem that integrates data from disparate systems, powered by high-value data, standardized measures, AI-enabled analytics, and healthcare domain expertise to transform complex information into actionable insights. These tools support measurable improvements in clinical quality, revenue cycle management, cost optimization, population health, and operational efficiency for clients such as academic medical centers, community hospitals, physician practices, and accountable care organizations. Founded in 2008 and headquartered in South Jordan, Utah, Health Catalyst Inc. emphasizes security and compliance, with certifications for products like Twistle, Lumeon, and Upfront, positioning it as a key enabler of data-informed healthcare transformation.
CEO Mr. Benjamin Albert · 1,200 employees · United States · https://www.healthcatalyst.com